Plasma viscosity and erythrocyte deformability play a key role in maintaining and regulating microcirculation. An improved blood flow, due to low blood viscosity, leads to an improvement in microcirculation, which stands the interactions between rheologic factors and the surrounding tissue (1). Under low flow conditions, red cell aggregation causes rheologic obstruction of the microcirculation and an impaired microcirculation has a rheologic, functional, and structural role with respect to damage of involved organs and tissues. Local haemodynamic shear stress modulates endothelial phenotype, so contributing to the progression of atherogenesis, in particular at sites vulnerable to lesion formation where unidirectional laminar flow is disturbed. Nitric oxide (NO) is released by the endothelium in response to shear stress and plays a crucial role in flow-mediated vasodilatation (2,3); pharmacologic inhibition or a genetic deficiency of endothelial NO synthase impairs endothelium-dependent vasodilatation and increases vascular resistance (4, 5) .
Finally, in vitro and in vivo studies (11) (12) (13) (14) suggested a role for NO in modulating the red blood cell deformability. Moreover, impairing NO availability, due to mutations in gene encoding for endothelial NO synthase (eNOS), might contribute to reduced shear stress, so increasing the plasma viscosity and influencing the red blood cell deformability. To the best of our knowledge, no information is available about the role of eNOS gene polymorphisms in affecting blood viscosity and red cell deformability.
To evaluate the contribution of the eNOS gene T-786C, G894T, and 4a/4b polymorphisms in modulating haemorheologic state, we investigated the relationship between the eNOS gene and haemorheologic profile in a clinical condition characterized by a microcirculatory disorder such as idiopathic sudden sensorineural hearing loss (ISSHL), in which both an impaired whole-blood and red blood cell filterability have been described (15, 16) .
MATERIALS AND METHODS

Patients and Control Subjects
We performed an observational case-control study on 80 consecutive Italian ISSHL patients, 41 males and 39 females, referred to the Thrombosis Centre, Azienda OspedalieroUniversitaria Careggi (Florence, Italy). All patients underwent a complete audiologic and physical examination. The diagnosis of ISSHL was made by experienced audiologists of Audiological Clinic of the University of Florence. Hearing loss patients with circulatory disorders, viral infections, or a history of venous thrombosis or neurologic diseases were excluded from the study. Other exclusion criteria were cigarette smoking, diabetes mellitus, hypertension, dyslipidemia, and trauma.
A detailed history, regarding onset of symptoms, earlier ear and hearing disease, hereditary factors, concomitant diseases, and bleeding tendency, was obtained from each patient.
The control population included 80 healthy subjects, 38 males and 42 females, comparable for gender and age with normal hearing and with no vascular disease, recruited from partners and friends of patients. Consanguineous subjects were excluded; patients and controls were white and drawn from the same area (Central Italy). Written informed consent was obtained from all participants after they were informed about the nature and the object of the study. The work complied with the principles of the Declaration of Helsinki and was approved by the ethic committee of the University of Florence.
Genetic Analysis
eNOS polymorphisms were analyzed after genomic DNA extraction from peripheral blood leukocytes using a QIAmp Blood Kit (QIAGEN, Hilden, Germany).
eNOS T-786C Polymorphism
The eNOS T-786C polymorphism was analyzed with polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Reactions were performed using the following primers: 5'-GTGTACCCCACCTGCATTCT-3' (sense) and 5'-CCCAGCAAGGATGTAGTGAC-3' (anti-sense). We amplified DNA (100 ng) in a final volume of 20 µL at an annealing temperature of 60°C using a DNA thermal cycler.
The PCR detection was followed by Turbo Nae restriction endonuclease digestion for 4 hours at 37°C and resolution by electrophoresis on 2% agarose gel. The 306-bp PCR product was cleaved into 225-bp and 81-bp fragments in the presence of a C at nucleotide -786, but not in its absence.
eNOS 4a/4b Polymorphism
The eNOS 4a/4b polymorphism was analyzed with PCR amplification; reactions were performed using the following primers: 5'-CTATG-GTAGTGCCTTGGCTGGAGG-3' (sense) and 5'-ACCGCCCAGGGAACTCCGCT-3' (anti-sense).
The DNA was amplified in a final volume of 20 µL at an annealing temperature of 58°C. The amplified products were electrophoresed on a 3.5% agarose gel. The four repeats allele (rare variant 4a) consisted of an 183-bp band and the five repeats allele (normal variant 4b) on a band of 210 bp.
eNOS G894T Polymorphism
The eNOS G894T polymorphism detection was performed with real-time fluorescence PCR through Light Cycler instrument (Roche Diagnostics).
PCR and melting curve determination were performed in a final volume of 20 µL using 10 pmol of each primer NOSF (5'-CACTCCC-CACAGCTCTGCAT-3') and NOSR (5'-CAATCC-CTTTGGTGCTCACG-3'), and 4 pmol of each probe (Anchor probe and Sensor probe). The anchor probe (5'-LC Red 640-CCTTCTGCCCCCC-GAGCTGGTCC-3'-P) was 5' labeled with the LCRed 640 fluorophore and phosphorylated (P) at its 3' end to prevent probe elongation by the Taq polymerase. The Sensor probe (5'-CCCCAGAT-GATCCCCCAGAACTC-3'FLU) was labeled with fluorescein. DNA was amplified at an annealing temperature of 62°C.
The typical melting curve pattern is a single melting peak at a temperature of 65.5°C. For the wild type, the plot is a single melting peak at a temperature of 60.5°C. Heterozygous patients show two melting peaks (60.5°C and 65.5°C) (17) .
Haemorheologic Profile
Venous blood samples were obtained from overnight fasting subjects in a resting condition in the morning (from 8 to 10 AM) by venupuncture of the antecubital vein with minimum stasis. Twenty milliliters of blood was anticoagulated with EDTA according to the guidelines of the International Committee for Standardization in Haematology (18) to perform the haemorheologic profile.
Haemorheologic studies were performed by assessing whole blood viscosity (WBV), plasma viscosity (PLV), and the erythrocyte filtration test, which is used to determine red blood cell deformability (19) . WBV and PLV were measured at 37°C using the Rotational Viscosimeter (bob in cup type) Low Shear 30 (Contraves, Zurich, Swissland). WBV was analyzed at shear rates of 0.512 sec -1 and 94.5 sec -1 . The PLV test was performed at 94.5 sec -1 shear rate. WBV was determined at native hematocrit. Erythrocyte filtration test was performed after separation of erythrocytes from plasma and buffy coat by centrifugation at 3000xg for 15 minutes at 4°C. Erythrocyte layers were washed three times with 10 volumes of 10 mmol/L isotonic buffer saline solution (pH 7.4; osmolarity 295 mmol/L) containing glucose and albumin and resuspended by adjusting hematocrit at 5%. The suspension was prefiltered before final testing by passage through small columns of Imugard cotton wool (IG 500) (Terumo Tokio, Japan) to eliminate leukocytes (20) . The erythrocyte deformability was measured with a microcomputer assisted filtrometer, model MF4 (Myrenne GmbH, Germany) as reported by Ramakrishnan and colleagues (20) . The initial flow rate from the microcomputer generated curves were taken for assessing the deformability index (DI) of the red blood cell, according to Ramakrishnan and colleagues (20) .
Statistical Analysis
Statistical analysis was performed using SPSS (Chicago, USA) for Windows (Version 11.5, Copyright SPSS Inc.). The Hardy-Weinberg equilibrium for genotype distribution and allele frequency was estimated with the chi-square test. Established risk factors for ISSHL were identified by univariate analysis. The relationship between genetic variables and ISSHL was determined by multivariate logistic regression analysis after adjustment for traditional risk factors. A p value less than 0.05 was considered significant. The analysis was based on a dominant model of inheritance. DI was used as measure of the erythrocyte deformability. The student t test for independent samples was used for comparisons between single groups.
RESULTS
Demographic and clinical characteristics of patients and controls are reported in Table 1 .
eNOS Polymorphisms eNOS gene genotype distribution and allele frequency were in agreement with those predicted by Hardy-Weinberg equilibrium in patients and controls. The genotype distribution and allele frequency of the eNOS gene T-786C, G894T, and 4a/4b are reported in Table 2 . A significantly higher prevalence of eNOS -786C and 894T, but not of 4a allele, was observed in patients in comparison to control subjects.
When we assumed a dominant model of inheritance (e.g., eNOS -786CC+TC vs. -786TT), a significant association between the eNOS gene -786C and 894T rare variants and the disease was found (Table 3) . The multivariate analysis, adjusted for gender, age, and traditional vascular risk factors (hypertension, dyslipidemia, and smoking habit) revealed that the eNOS 894Trare variant was an independent predisposing factor to ISSHL (Table 3) .
When the eNOS -786C and 894T rare variants were present (-786CC+TC and 894TT+GT combined genotype), the OR for the predisposition to the disease was 2.99 (CI95%, 1.43-6.2; p = 0.003), and in subjects carrying all three eNOS rare alleles (-786CC+TC and 894TT+GT and 4a4a+4a4b combined genotype), the OR was 3.6 CI95% 1.83-7.18, p = 0.0002).
Haemorheologic Profile
Data regarding the haemorheological profile showed that WBV (at both low and high shear rates), and Deformability Index, were significantly different between patients and controls (Table 4) . (27) 18 (22) Smoking habit (%) 10 (13) 11 (14) Diabetes mellitus --History of cardiovascular disorders --*Median and range. From the univariate analysis, a significant association between WBV, at both low and high shear stress, and DI and the disease was observed; after adjustment for the other variables (gender, age, hypertension, diabetes, dyslipidemia, smoking habit, fibrinogen, and hematocrit), WBV (94.5 s -1 ), and DI were found to be independently associated with ISSHL (Table 5) .
eNOS GENE AFFECTS HAEMORHEOLOGICAL STATE
Haemorheologic Parameters and eNOS Polymorphisms
We observed a higher percentage of altered red cell deformability in subjects carrying the eNOS rare variants in comparison to those carrying the wild-type allele: DI was altered in 73.2%, 70%, and 74% of patients carrying the eNOS -786C, 894T, and 4a rare variants, respec- tively, and in 41.7%, 53.3%, and 56.6% of patients carrying the -786T, 894G, and 4b wild-type alleles. The same pattern was observed in control subjects: red cell deformability was altered in 9.3%, 8.6%, and 8.3% of controls carrying the eNOS -786C, 894T, and 4a rare variants, respectively, and in 2.7%, 4.4%, and 5.4% controls carrying the -786T, 894G, and 4b wild-type alleles.
eNOS GENE AFFECTS HAEMORHEOLOGICAL STATE
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To evaluate the influence of eNOS polymorphisms on red cell deformability apart from the disease, we used a logistic model in which red cell deformability was considered the dependent variable; from the univariate analysis, eNOS -786C and 894T rare alleles significantly affected the altered red cell deformability, and the influence on this parameter was higher in subjects carrying these two variants (Table 6 ). After adjustment for traditional vascular risk factors , the eNOS rare variants remained associated with altered red cell deformability, and the presence of -786C and 894T alleles significantly modified the influence on red cell deformability (Table 6 ).
DISCUSSION
To our knowledge, this is the first report in which the relationship between eNOS gene polymorphisms and haemorheologic state has been documented in a clinical model of microcirculatory disorder.
Our study provides a new insight into the role of NO in influencing blood viscosity and, in particular, into the effect of eNOS polymorphisms in affecting red blood cell deformability.
Plasma viscosity and erythrocyte deformability play a key role in maintaining and in regulating microcirculation. Erythrocyte morphology is relevant in rheological flow, since the deformability of the circulating cells greatly influences the rheologic properties of the blood. Under pathologic conditions the red cell deformability is altered, affecting the rheologic environment at microcirculatory level.
Our results showed that WBV at medium/high shear rates and red cell deformability are independently associated with ISSHL, are in keeping with previous studies that reported a relationship between whole blood viscosity and sensorineural hearing impairment, and suggested a role for increased blood viscosity and plasma viscosity in the etiology of sudden deafness (15, 21, 22) .
The endothelium represents a relevant structural and functional component of the microcirculation. Endothelial cells modulate vascular function by secretion of mediator proteins and molecules (23) , which regulate vascular smooth muscle tone and growth. One of the key factor contributing to vessel wall homeostasis and vascular tone regulation is NO, a relevant endothelium-derived relaxing factor synthesized from Larginine. Previous studies reported a role for eNOS polymorphisms in vascular tone regulation and in various events during atherogenesis (24, 25) ; our data showed that eNOS polymorphisms affected both acute coronary syndromes (26) and carotid atherosclerosis susceptibility (27) , so influencing macrovascular events. Moreover, we previously demonstrated (28) a role for eNOS G894T polymorphism in the pathogenesis of systemic sclerosis, in which vasoconstriction and morphologic changes of the dermal microvasculature might be mediated by underproduction of endothelial nitric oxide.
Experimental studies (11, 13, 14, 29) suggested that NO may modulate red blood cell deformability and aggregation with a concentration-dependent effect, and demonstrated that inhibition of NOS resulted in a significant impairment of red blood cell deformability, which could be restored by NO donors, so generating the hypothesis of a role for NO in regulating the maintenance of normal deformability. The physical properties of the membrane skeleton are the major determinants of the red blood cell deformability and the maintenance of the red cell deformability depends on the metabolic state of the cell (30) , and on the membrane mechanical properties (31, 32) . Bor-Kucukatay and colleagues (2) demonstrated that NO plays a role in maintaining red cell deformability by preserving the mechanical propriety and suggested that inhibition of NOS resulted in impairment of red blood cell deformability. The mechanism responsible for the effect of NO on red cell deformability has yet to be fully defined. A NO regulatory effect on red cell deformability by soluble guanylate cyclase has been hypothesized (33) , and experimental studies showed a role for NO in modulating ion transport across the red cell membrane (34, 35) .
To date, L-arginine, a precursor of NO, exhibits activity as a vasodilator, platelet-aggregation inhibitor, and modulator of immunologic processes and epithelial permeability (36) ; so arginine supplementation might represent a therapeutic benefit in the presence of eNOS polymorphisms related to reduced NO availability.
CONCLUSION
Our results indicate that the presence of eNOS gene rare variants, which are related to impaired NO availability, affects red blood cell deformability and blood viscosity, so possibly contributing to microcirculatory alterations such as those found in ISSHL, which represents a suitable model.
Further studies are needed to address the molecular mechanisms by which the eNOS gene is involved in the modulation of haemorheologic profile in patients suffering from other microvascular disorders.
